How big is the Insomnia Treatment Market?

The Insomnia Treatment Market size is expected to reach USD 3.58 billion in 2024 and grow at a CAGR of 5.16% to reach USD 4.60 billion by 2029. Read More

What is the current Insomnia Treatment Market size?

In 2024, the Insomnia Treatment Market size is expected to reach USD 3.58 billion. Read More

Who are the key players in Insomnia Treatment Market?

Pfizer Inc., Sanofi S.A., Takeda Pharmaceutical Company Ltd., Merck & Co. and Electromedical Products International Inc. are the major companies operating in the Insomnia Treatment Market. Read More

Which is the fastest growing region in Insomnia Treatment Market?

Asia-Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029). Read More

Which region has the biggest share in Insomnia Treatment Market?

In 2024, the North America accounts for the largest market share in Insomnia Treatment Market. Read More

What years does this Insomnia Treatment Market cover, and what was the market size in 2023?

In 2023, the Insomnia Treatment Market size was estimated at USD 3.40 billion. The report covers the Insomnia Treatment Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Insomnia Treatment Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029. Read More

Insomnia Treatment Market Trends

Market Trends of Insomnia Treatment Industry

Orexin Antagonist Segment is Expected to Hold a Significant Share in the Market During the Forecast Period

The orexin antagonist segment is expected to dominate the growth of the segment during the forecast period due to the reduced efficacy and harmful side effects that constrain the use of many treatment options for several patients. Some of the orexin receptor antagonists include suvorexant, lemborexant, and daridorexant. These drugs are potent dual orexin receptor antagonists that block both receptors, i.e., OX1R and OX2R. They stimulate sleep by inhibiting orexin-A and B, neuropeptides that promote wakefulness.
Suvorexant (MK-4305, Merck) is one of the first of a new class of drugs for treating insomnia known as ORAs (orexin receptor antagonists). The tablets support the natural transition from sleeplessness to sleep by inhibiting the arousal system's wakefulness-promoting orexin neurons. Suvorexant advances sleep onset and sleep maintenance. This distinctive alternative has advantageous permissibility and a restricted side-effect profile.
The increasing product approvals and product development activities are expected to contribute to the growth of the segment during the forecast period. For instance, in October 2022, Idorsia Pharmaceuticals Japan announced positive top-line results of the Japanese Phase 3 study investigating 25 and 50 mg doses of Idorsia's dual orexin receptor antagonist, daridorexant, in 490 randomized adult and elderly patients (30.1% 65 years) with insomnia.
Similarly, in February 2024, the first selective orexin-1 receptor antagonist (SO1RA) was investigated during clinical trials. The orexin system consists of two neuropeptides (orexins A and B) and two receptors (OX1 and OX2).
Due to the apparent benefits associated with the orexin class of drugs, increasing product approvals, and the rising prevalence of insomnia or difficulty falling asleep, the insomnia treatment market is expected to grow steadily during the forecast period.

Insomnia Treatment Market: People who get less than seven hours of sleep per night (in %), By Age, United States, 2023

Understand The Key Trends Shaping This Market

Download PDF

North America is Expected to Dominate the Insomnia Treatment Market During the Forecast Period

North America is expected to hold a significant share of the insomnia treatment market. The growing need for sleep disorder treatment in the United States and Canada, coupled with the increasing prevalence of sleep disorders, is expected to drive the market during the forecast period.
For instance, data published by the government of Canada in June 2022 mentioned that one-third of Canadians were not getting enough sleep, with thousands of people suffering from insomnia and other sleep disorders. Such incidences of sleep disorders among the population in this region are expected to drive the market's growth.
The increasing government support in the form of funding for insomnia treatment is expected to contribute to the market's growth. For instance, in June 2022, the Minister of Health released funding of USD 2.86 million (CAD 3.8 million) to support research on sleep health and insomnia. The government of Canada supported this initiative through the Canadian Institutes of Health Research (CIHR) in partnership with Esai Limited and Mitacs. Such funding in North America is expected to contribute to the market's growth during the forecast period.
According to the National Library of Medicine, Biotech Information, in 2023, inadequate sleep resulted in a significant economic cost of over USD 411 billion in the United States. This rise in financial burden is consequently affecting the insomnia treatment market in the country.
Thus, the growing prevalence of sleep disorders and frequent product launches, coupled with increasing government funding for insomnia treatments, are expected to contribute to the market's growth during the forecast period.